Multimodal Investigation of Intracranial Clot Environment
MISO
1 other identifier
observational
200
1 country
1
Brief Summary
Analysis of peri clot blood collected at the acute phase of stroke in order to understand physiopathological mechanisms involved in the cerebrovascular damage
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 28, 2020
CompletedFirst Posted
Study publicly available on registry
June 9, 2020
CompletedStudy Start
First participant enrolled
March 14, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2025
CompletedMay 29, 2024
May 1, 2024
4.2 years
May 28, 2020
May 27, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Metalloproteinase 9 quantification
60 months
Metalloproteinase 2 quantification
60 months
Secondary Outcomes (1)
Cytokines levels
60 months
Study Arms (1)
Patients with acute ischemic stroke
Patients undergoing Mechanical Thrombectomy for large vessel occclusion with acute ischemic stroke
Interventions
Blood sampling at the site of intracranial occlusion during Mechanical Thrombectomy
Eligibility Criteria
Patients undergoing Mechanical Thrombectomy for large vessel occclusion with acute ischemic stroke
You may qualify if:
- Over 18 years of age,
- Non-dependent for activities of daily living prior to the onset of the MI (Modified Rankin Score \>2)
- Having an occlusion of a large arterial trunk proven by imaging (angio-MRI or angio-scanner).
You may not qualify if:
- Patients initially admitted but for whom endovascular treatment will not finally be performed (re-infusion, catheterization failure...) will be excluded from the study.
- Major patients under guardianship or curatorship or patients deprived of liberty
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospital, Montpellierlead
- Genomic Institute of Montpelliercollaborator
Study Sites (1)
University Hospital of Montpellier
Montpellier, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Vincent COSTALAT, MD PhD
Montpellier University Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 28, 2020
First Posted
June 9, 2020
Study Start
March 14, 2021
Primary Completion
June 1, 2025
Study Completion
October 1, 2025
Last Updated
May 29, 2024
Record last verified: 2024-05
Data Sharing
- IPD Sharing
- Will not share